Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Non-Current Debt (2016 - 2025)

Gsk has reported Non-Current Debt over the past 10 years, most recently at $19.6 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $19.6 billion for Q4 2025, up 4.35% from a year ago — trailing twelve months through Dec 2025 was $19.6 billion (up 4.35% YoY), and the annual figure for FY2025 was $19.6 billion, up 4.35%.
  • Non-Current Debt for Q4 2025 was $19.6 billion at Gsk, up from $18.7 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for GLAXF hit a ceiling of $27.8 billion in Q4 2021 and a floor of $18.7 billion in Q4 2024.
  • Median Non-Current Debt over the past 5 years was $19.6 billion (2025), compared with a mean of $21.0 billion.
  • Biggest five-year swings in Non-Current Debt: decreased 28.05% in 2022 and later grew 4.35% in 2025.
  • Gsk's Non-Current Debt stood at $27.8 billion in 2021, then fell by 28.05% to $20.0 billion in 2022, then fell by 5.55% to $18.9 billion in 2023, then fell by 0.7% to $18.7 billion in 2024, then grew by 4.35% to $19.6 billion in 2025.
  • The last three reported values for Non-Current Debt were $19.6 billion (Q4 2025), $18.7 billion (Q4 2024), and $18.9 billion (Q4 2023) per Business Quant data.